Property:Drop-out reasons
This is a property of type Text.
F
Fallon et al. (2017) I: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies +
Side effects (n = 29, 14.6%), consent withdrawn (n = 8, 4%), death (n = 25, 68%) +
Fallon et al. (2017) II: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies +
Adverse Events n=13
Withdrawn by investigator n=1
Lack of efficacy n=1
Died during treatment n=9 +
Fallon et al. (2017) II: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies +
Adverse Events n=21
Withdrew consent n=2
Withdrawn by investigator n=1
Lack of efficacy n=1
Died during treatment n=23
Died post-treatment but before follow-up n=8
Died post follow-up n=3 +
Ferreira et al. (2004): Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: A double-blind randomized trial +
Did not receive the prescribed doses: n=2 because of intense mucositis and n=1 because of death caused by tumor progression +
Ferreira et al. (2004): Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: A double-blind randomized trial +
NA +
Frankling et al. (2021): ‘Palliative-D’ - Vitamin D Supplementation to Palliative Cancer Patients: A Double Blind, Randomized Placebo-Controlled Multicenter Trial +
Death due to cancer +
Frankling et al. (2021): ‘Palliative-D’ - Vitamin D Supplementation to Palliative Cancer Patients: A Double Blind, Randomized Placebo-Controlled Multicenter Trial +
Death due to cancer +
Freedland et al. (2020): A Randomized Controlled Trial of a 6-month low carbohydrate intervention on disease progression in men with recurrent prostate cancer: Carbohydrate and Prostate Study 2 (CAPS2) +
Started ADT treatment (n=6); withdrew (n=1); lost to follow up (n=1) +
Freedland et al. (2020): A Randomized Controlled Trial of a 6-month low carbohydrate intervention on disease progression in men with recurrent prostate cancer: Carbohydrate and Prostate Study 2 (CAPS2) +
Started ADT treatment (n=2); withdrew (n=1); started radiation (n=1) +
G
Ghoreishi et al. (2007): Effect of vitamin E on chemotherapy-induced mucositis and neutropenia in leukemic patients undergoing bone marrow transplantation +
No drop-out reported +
Ghoreishi et al. (2007): Effect of vitamin E on chemotherapy-induced mucositis and neutropenia in leukemic patients undergoing bone marrow transplantation +
No drop-out reported +
Goossens et al. (2016): Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial +
3 months follow-up: randomized in error, not meeting inclusion criteria n=6, death n=1, withdrew consent n=8;
Follow-up over 3 years: adverse events n=2, withdrew consent n=24 +
Goossens et al. (2016): Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial +
3 months follow-up: randomized in error, not meeting inclusion criteria n=10, cystectomy n= 3, withdrew consent n=5;
Follow-up over 3 years: reccurence n=1, adverse events n=2, withdrew consent n=14 +
Gorgu et al. (2013): The effect of zinc sulphate in the prevention of radiation induced oral mucositis in patents with head and neck cancer +
NI +
Gorgu et al. (2013): The effect of zinc sulphate in the prevention of radiation induced oral mucositis in patents with head and neck cancer +
NI +
Grimison et al. (2020): Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial +
Discontinued after placebo (n = 2):
chemotherapy stopped (n = 1); patient preference (n = 1) +
Grimison et al. (2020): Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial +
Discontinued after THC:CBD (n = 4):
Death (n = 1); failure to comply (n = 1); chemotherapy stopped (n = 1); patient preference (n = 1) +
Gujral et al. (2001): Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers +
Personal reasons (n=1); died after the end of radiation (n=2) +
Gujral et al. (2001): Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers +
Personal reasons (n=1) +
H